Company news

Aptamer Group PLC news in 2025

Aptamer Group PLC's news releases, calls and decks from 2025, newest first.

View company

Aptamer signs licensing agreement with Alphazyme

December 23, 2025

Licensing agreement with Twist Bioscience

December 16, 2025

Results of 2025 Annual General Meeting

November 27, 2025

AGM Statement

November 27, 2025

Strong contract wins build commercial momentum

November 14, 2025

New contract with top five pharma company

November 4, 2025

Posting of Annual Report and Notice of AGM

November 3, 2025

Full Year Results for the 12mths to 30 June 2025

October 14, 2025

New contract with top 10 pharma

October 13, 2025

Notice of Results, Analyst & Investor Presentation

October 10, 2025

Major top 3 global pharma contract win

October 8, 2025

Investor Event and Presentation

September 26, 2025

New contract with Metir plc

September 11, 2025

Notification of dealings by a director/PDMR

September 9, 2025

Therapeutic development agreement with Invizius

September 2, 2025

Block Listing Interim Review

August 28, 2025

Biomarker Discovery Service Launch

August 27, 2025

Update on licensing and development progress

August 22, 2025

Exercise of warrants

August 19, 2025

Holding(s) in Company

August 18, 2025

Contract extension with global pharma partner

August 18, 2025

Investor Technical Webinar

August 8, 2025

Investor Webinar

July 31, 2025

Trading Update

July 31, 2025

Result of General Meeting

July 24, 2025

Additional work commissioned by Unilever

July 21, 2025

Issue of Equity in lieu of Non-Exec Director Fees

July 18, 2025

Posting of Circular and Notice of General Meeting

July 8, 2025

Placing to raise £2.0 million

July 4, 2025

Liver fibrosis breakthrough with Optimer® platform

June 30, 2025

Agreement with global life sciences leader

June 25, 2025

Unilever second Optimer development programme

May 30, 2025

Aptamer Announces New Data at ASGCT

May 15, 2025

Optimer licensing agreements and repeat contracts

May 15, 2025

Alzheimer’s test advanced and royalty agreement

May 6, 2025

Licensing agreed for Optimer as vaccine adjuvant

April 30, 2025

Aptamer Presenting at ASGCT Annual Meeting

April 29, 2025

New Corporate Presentation and Investor Factsheet

April 24, 2025

Interim Results

March 11, 2025

TR-1: Standard form notification of major holdings

February 27, 2025

Notice of Results and Investor Presentation

February 25, 2025

Issue of Equity in lieu of Director fees

January 28, 2025

Calls in 2025

Decks in 2025